Video

Multiple Myeloma in the Elderly

Publish date: December 18, 2009

 

In the VISTA trial, the Spanish Myeloma Group created an induction regimen of bortezomib, melphalan, and prednisone that elderly patients could tolerate. This year the group took that regimen a step further.

Recommended Reading

Lymphoma and Biologics
MDedge Hematology and Oncology
Survival improves for AYAs with leukemia and lymphoma
MDedge Hematology and Oncology
Novel agent more effective than standard therapy in NHL
MDedge Hematology and Oncology
Potential cause of R-CHOP failure ruled out
MDedge Hematology and Oncology
Ofatumumab receives accelerated approval from FDA
MDedge Hematology and Oncology
Panobinostat shows promise in refractory Hodgkin lymphoma
MDedge Hematology and Oncology
Vorinostat demonstrates consistent safety
MDedge Hematology and Oncology
Most effective first-line therapy for T-PLL
MDedge Hematology and Oncology
Fostamatinib successfully targets the B-cell receptor
MDedge Hematology and Oncology